Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: A literature review

Advances in Therapy

Volumn 25, Issue 9, 2008, Pages 842-857

  Siegert, Scott W K ^a,b   Holt, Robert J ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

Intravenous hematin; Panhematin; Pharmacokinetics; Porphyria; Toxicology

Indexed keywords

HEMATOLOGIC AGENT; HEMIN; SERUM ALBUMIN;

ACUTE INTERMITTENT PORPHYRIA; CHEMISTRY; DOSE RESPONSE; DRUG STABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; HEMATOLOGIC AGENTS; HEMIN; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; PORPHYRIA, ACUTE INTERMITTENT; SERUM ALBUMIN;

EID: 58149359118     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0094-y     Document Type: Review

References (41)

1. Panhematin (hemin for injection) package insert. Deerfeld, IL: Ovation Pharmaceuticals, Inc., USA; August 2006.
2. Pierach CA. Hematin therapy for the porphyric attack. Semin Liver Dis. 1982;2:125-131.
3. Lamon JM, Frykholm BC, Hess RA, Tschudy DP. Hematin therapy for acute porphyria. Medicine. 1979;58:252-269. (Pubitemid 9176274)
4. Mustajoki P, Tenhunen R, Pierach C, Volin L. Heme in the treatment of porphyrias and hematological disorders. Semin Hematol. 1989;26:1-9. (Pubitemid 19136195)
5. Dhar G, Bossenmaier I, Petryka Z, Cardinal R, Watson C. Effects of hematin in hepatic porphyria. Further studies. Ann Intern Med. 1975;83:20-30.
6. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991;86:1050-1056.
7. Chung WY, Lee JM, Lee WY, Surh YJ, Park KK. Protective Effects of hemin and tetrakis(4-benzoic acid)porphyrin on bacterial mutagenesis and mouse skin carcinogenesis induced by 7, 12-dimethylbenzaanthracene. Mutat Res. 2000;472:139-145.
8. Park KK, Park JH, Jung YJ, Chung WY. Inhibitory Effects of chlorophyllin, hemin and tetrakis(4-benzoic acid) porphyrin on oxidative DNA damage and mouse skin infammation induced by 12-O-tetradecanoylphorbol-13-acetate as a possible anti-tumor promoting mechanism. Mutat Res. 2003;542:89-97.
9. Al-Waili NS, Butler GJ. Phototherapy and malignancy: possible enhancement by iron administration and hyperbaric oxygen. Med Hypotheses. 2006;67:1148-1158. (Pubitemid 44314153)
10. Kneidinger M, Gleixner K, Kondo R, et al. Heme oxygenase-1 (HO-1)/heat shock protein 32 (Hsp32) as a novel survival factor and target in AML. Poster presented at: Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida.
11. Sato H, Siow RC, Bartlett S, et al. Expression of stress proteins heme oxygenase-1 and-2 in acute pancreatitis and pancreatic islet betaTC3 and acinar AR42J cells. FEBS Lett. 1997;405:219-223. (Pubitemid 27136514)
12. Nakamichi I, Habtezion A, Zhong B, Contag CH, Butcher EC, Omary MB. Hemin-activated macrophages home to the pancreas and protect from acute pancreatitis via heme oxygenase-1 induction. J Clin Invest. 2005;115:3007-3014. (Pubitemid 41567566)
13. Ruutu T, Volin L, Tenhunen R. Haem arginate as a treatment for myelodysplastic syndromes. Br J Haematol. 1987;65: 425-428. (Pubitemid 17073758)
14. Volin L, Ruutu T, Knuutila S, Tenhunen R. Heme arginate treatment for myelodysplastic syndromes. Leuk Res. 1988;12:423-431.
15. Timonen TT, Kauma H. Terapeutic Effect of heme arginate in myelodysplastic syndromes. Eur J Haematol. 1992;49: 234-238. (Pubitemid 23024285)
16. Rochant H, Fenaux P, Guerci A, et al. Results of heme arginate treatment of myelodysplastic syndromes. A multicenter phase II study of the French group of myelodysplastic syndromes. Blood. 1996;88(suppl. 1):210b:3566.
17. Devadas K, Dhawan S. Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. J Immunol. 2006;176:4252-4257. (Pubitemid 44264404)
18. Levere RD, Gong Y, Kappas A, et al. Heme inhibits human immunodefciency virus 1 replication in cell cultures and enhances the antiviral Effect of zidovudine. Proc Natl Acad Sci USA. 1991;88:1756-1759. (Pubitemid 21916304)
19. Staudinger R, Abraham NG, Levere RD, Kappas A. Inhibition of human immunodefciency virus-1 reverse transcriptase by heme and synthetic heme analogs. Proc Assoc Am Physicians. 1996;108:47-54.
20. Chen Y, Zhu X, Zhao X, Xing H, Li Y. Hemin, a heme oxygenase-1 inducer, improves aortic endothelial dysfunction in insulin resistant rats. Chin Med J. 2008;121:241-247. (Pubitemid 351234593)
21. Fischer H, Orth H. Die Chemie des Pyrrols. B II. I. Halfe. Akademische Verlagsgesellschaf. Leipzig;1937:37-38.
22. Simionatto C, Cabal R, Jones R, Galbraith R. Trombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am J Med. 1988;85:538-540.
23. Goetsch C, Bissell D. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235-238. (Pubitemid 16097126)
24. Morris D, Dudley M, Pearson R. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med. 1981;95:700-701. (Pubitemid 12173174)
25. Glueck R, Green D, Cohen I, Ts'ao C. Hematin: unique Effects of hemostasis. Blood. 1983;61:243-249.
26. Green D, Reynolds N, Klein J, Kohl H, Ts'ao C. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361-369. (Pubitemid 13009610)
27. Jones R. Hematin-derived anticoagulant: generation in vitro and in vivo. J Exp Med. 1986;163:724-739. (Pubitemid 16141973)
28. Cannon J, Yunker M, Luoma N. The Effect of aggregation inhibitors and antioxidants on the stability of hemin solutions. PDA J Pharm Sci Technol. 1995;49:77-82.
29. Cannon J. Pharmaceutics and drug delivery aspects of heme and porphyrin therapy. J Pharm Sci. 1993;82:435-446. (Pubitemid 23150443)
30. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008;60:79-127. (Pubitemid 351439218)
31. Smith A, Morgan W. Hemopexin-mediated heme uptake by liver: characterization of the interaction of heme-hemopexin with isolated rabbit liver plasma membranes. J Biol Chem. 1984;259:12049-12053. (Pubitemid 14022137)
32. Noyer C, Immenschuh S, Liem H, Muller-Eberhard U, Wolkof A. Initial heme uptake from albumin by short-term cultured rat hepatocytes is mediated by a transport mechanism difering from that of other organic anions. Hepatology. 1998;29: 150-155. (Pubitemid 28299996)
33. Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta. 2001;312:13-23. (Pubitemid 32913576)
34. Sears D, Huser H. Plasma hematin-binding and clearance in the rhesus monkey. Proc Soc Exp Biol Med. 1966;121:11-16.
35. Petryka Z, Dhar G, Bossenmaier I. Hematin clearance in porphyria. Conference proceedings. 1st International Porphyrin Meeting, 1975. Basel: Karger; 1976: 259-256.
36. ® (hemin for injection). Ovation Pharmaceuticals, Inc., Illinois, USA.
37. Lips D, Pierach C, Edwards P. Hematin toxicity in rats. Toxicol Lett. 1978;2: 329-332. (Pubitemid 9066161)
38. Anderson W, Morrison D, Williams E. Pathologic changes following injections of ferrihemate (hematin) in dogs. Arch Pathol. 1942;33:589-602.
39. Waters L, Roberts R. Effect of several endogenous substances-including porphyrins, hematin, and carbon monoxide-on hepatic clearance of sulfobromphthalein. Toxicol Lett. 1974;2:223-229.
40. Corcoran A, Page I. Renal damage from ferroheme pigments myoglobin, hemoglobin, hematin. Tex Rep Biol Med. 1945;3:528-544.
41. Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978;203: 437-443. (Pubitemid 8358467)